21 Result(s)
within
Brian G. M. Durie
Oncology
-
Article
Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy
Objective methods have been developed to quantitate results of the in vitro human tumor stem cell assay, the degree of the association between the in vitro assay and clinical response as well as the likelihood...
-
Article
Treatment of patients with refractory myelogenous leukemia with BCOMM [1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)]
Ten patients with AML refractory to anthracyclines and cytosine arabinoside were treated with vincristine 1.4 mg/m2 and methotrexate (MTX) 2.5 gm/m2 by intravenous (IV) bolus on day 1 [citrovorum factor (CF) resc...
-
Chapter
Macrophages as an Important Source of Paracrine IL6 in Myeloma Bone Marrow
Interleukin 6 (IL6) is a pleiotropic cytokine which has been shown to be a very potent growth factor for myeloma cells, particularly cells derived from patients with aggressive clinical disease (1,2). Although it...
-
Chapter
Workshop on growth factors
The ‘Workshop on Growth Factors’ which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be im...
-
Chapter and Conference Paper
Cytogenetic Abnormalities in Multiple Myeloma
Cytogenic studies in multiple myeloma have been very difficult because of the predominantly low proliferative activity in this disease (1-7). In the series reported to date the most commonly affected chromosomes ...
-
Article
Phase II evaluation of bisantrene in refractory multiple myeloma
-
Chapter
The Role of Anatomic and Functional Imaging in Myeloma
-
Article
Awareness, concern, and communication between physicians and patients on bone health in cancer
This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).
-
Article
Observational study of multiple myeloma in Latin America
Relatively little is known about the outcomes of multiple myeloma in Latin America, a world region where incorporation of novel agents is generally slow. In the current retrospective-prospective study, we aime...
-
Article
Open AccessRecommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myel...
-
Article
Open AccessClinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term sur...
-
Article
Open AccessImpact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Pre...
-
Article
Open AccessLonger term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival ...
-
Article
Open AccessInternational Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitatin...
-
Article
Open AccessIceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland S...
-
Article
Open AccessTreatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry
-
Article
Open AccessMonoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undeterm...
-
Article
Open AccessDefining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic...
-
Article
Open AccessCorrection: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
-
Article
Open AccessDetermining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
Hemodilution of bone marrow (BM) aspirates is a limitation of multiparameter flow cytometry (MFC) in plasma cell disorders. There is a need for a validated approach for assessing sample quality and the distrib...
